- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 317/28 - Radicals substituted by nitrogen atoms
Patent holdings for IPC class C07D 317/28
Total number of patents in this class: 129
10-year publication summary
|
11
|
7
|
17
|
4
|
6
|
3
|
8
|
6
|
15
|
6
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| NanoVation Therapeutics Inc. | 72 |
17 |
| Arbutus Biopharma Corporation | 176 |
13 |
| NOK Corporation | 2238 |
5 |
| Novartis AG | 10612 |
4 |
| Ambrx, Inc. | 175 |
4 |
| Akagera Medicines, Inc. | 26 |
4 |
| Protiva Biotherapeutics, Inc. | 31 |
3 |
| The Scripps Research Institute | 1355 |
3 |
| Sirna Therapeutics, Inc. | 108 |
3 |
| Arbutus Biopharma Corporation | 39 |
3 |
| The Trustees of the University of Pennsylvania | 4390 |
2 |
| Alnylam Pharmaceuticals, Inc. | 1140 |
2 |
| Constellation Pharmaceuticals, Inc. | 211 |
2 |
| F.I.S. Fabbrica Italiana Sintetici S.p.A. | 131 |
2 |
| Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center | 166 |
2 |
| Nippon Soda Co., Ltd. | 892 |
2 |
| Toyo Gosei Co., Ltd. | 108 |
2 |
| The University of British Columbia | 1538 |
2 |
| Eisai R&D Management Co., Ltd. | 1204 |
2 |
| Integrated Nanotherapeutics Inc. | 11 |
2 |
| Other owners | 50 |